Evolus (EOLS) Asset Writedowns and Impairment (2019 - 2025)
Evolus' (EOLS) quarterly Asset Writedowns and Impairment came in at $2.2 million in Q3 2025, up 148.59% YoY from $889000.0 in Q3 2024, and up 214.37% on a QoQ basis from $703000.0 in Q2 2025.
Evolus (EOLS) Asset Writedowns and Impairment (2019 - 2025) Analysis & Trends
Evolus (EOLS) has 7 years of Asset Writedowns and Impairment data on file, last reported at $2.2 million in Q3 2025.
- Quarterly Asset Writedowns and Impairment rose 148.59% year-over-year to $2.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $4.8 million (up 172.44% YoY) and the FY2024 annual result came in at $2.4 million, up 70.07% from the prior year.
- Asset Writedowns and Impairment improved to $2.2 million in Q3 2025, from $703000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $2.2 million in Q3 2025 to a low of -$297000.0 in Q2 2021.
- A 5-year average of $528421.1 and a median of $465000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2021 — Asset Writedowns and Impairment slumped 76.6% — and 2024, when it soared 818.6%.
- Tracing EOLS's Asset Writedowns and Impairment over 5 years: stood at $88000.0 in 2021, then jumped by 167.05% to $235000.0 in 2022, then tumbled by 63.4% to $86000.0 in 2023, then soared by 818.6% to $790000.0 in 2024, then surged by 179.75% to $2.2 million in 2025.
- The last three Asset Writedowns and Impairment figures came in at $2.2 million (Q3 2025), $703000.0 (Q2 2025), and $1.1 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.21 Mn |
| Sep 30, 2025 | 2.21 Mn |
| Jun 30, 2025 | 703,000.00 |
| Jun 30, 2025 | 703,000.00 |
| Mar 31, 2025 | 1.05 Mn |
| Mar 31, 2025 | 1.05 Mn |
| Dec 31, 2024 | 790,000.00 |
| Dec 31, 2024 | 790,000.00 |
| Sep 30, 2024 | 889,000.00 |
| Sep 30, 2024 | 889,000.00 |
| Jun 30, 2024 | 582,000.00 |
| Jun 30, 2024 | 582,000.00 |
| Mar 31, 2024 | 188,000.00 |
| Mar 31, 2024 | 188,000.00 |
| Dec 31, 2023 | 86,000.00 |
| Dec 31, 2023 | 86,000.00 |
| Sep 30, 2023 | 1.01 Mn |
| Sep 30, 2023 | 1.01 Mn |
| Jun 30, 2023 | 69,000.00 |
| Jun 30, 2023 | 69,000.00 |